WFDC2 and neoplasm: In an interesting study it has been revealed that in the BRCA WT patients, HE4 performed as a predictive marker of chemosensitivity with a sensibility of 80% and a specificity of 100%; in BRCA mutated women, HE4 performed as a predictive marker of chemosensitivity in all patients: the ability to detect platinum-resistant patients before tumor relapse probably could open new therapeutic scenarios [40].